A Study Evaluating The PF-03084014 In Combination With Docetaxel In

See also
Status	Clinical Trial	Phase
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Active, not recruiting	`NCT04509596` - DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer	Phase 1
Recruiting	`NCT04122469` - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease	N/A
Completed	`NCT03045653` - Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer	Phase 2
Terminated	`NCT03322215` - HR+/HER2- Advanced Breast Cancer and Endocrine Resistance	Phase 2
Active, not recruiting	`NCT04059484` - Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer	Phase 2
Recruiting	`NCT04368442` - Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
Terminated	`NCT03709082` - Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer	Phase 1/Phase 2
Terminated	`NCT03642990` - NR in Chemo-induced Peripheral Neuropathy	Phase 2
Completed	`NCT04483505` - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.	Phase 1
Recruiting	`NCT03086785` - Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer	Phase 2
Terminated	`NCT04197999` - A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer	Phase 1
Not yet recruiting	`NCT06439693` - The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer	Phase 2
Not yet recruiting	`NCT03638765` - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer	Phase 1
Recruiting	`NCT06100874` - A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)	Phase 2
Completed	`NCT05609903` - Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
Active, not recruiting	`NCT04597580` - Personalised Disease Monitoring in Metastatic Breast Cancer
Completed	`NCT05301530` - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.	Phase 1
Active, not recruiting	`NCT03328884` - Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients	Phase 2
Recruiting	`NCT05837533` - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients	N/A

NCT number	NCT01876251
Study type	Interventional
Source	Pfizer
Contact
Status	Terminated
Phase	Phase 1
Start date	November 4, 2013
Completion date	December 24, 2015

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms